Impact of COVID-19 infection on the cardiovascular system: An evidence-based analysis of risk factors and outcomes
- PMID: 34511231
- PMCID: PMC7919539
- DOI: 10.1016/j.bpa.2021.02.003
Impact of COVID-19 infection on the cardiovascular system: An evidence-based analysis of risk factors and outcomes
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, emerged in late 2019 in Wuhan, China. The World Health Organization declared the virus a pandemic on March 11, 2020. Disease progression from COVID-19 infection has shown significant symptom manifestations within organ systems beyond the respiratory system. The literature has shown increasing evidence of cardiovascular involvement during disease course and an associated increase in mortality among infected patients. Although the understanding of this novel virus is continually evolving, it is currently proposed that the mechanism by which the SARS-CoV-2 virus contributes to cardiovascular manifestations involves the ACE2 transmembrane protein. The protein ACE2 is highly expressed in blood vessel pericytes, and infection can result in microvascular dysfunction and subsequent acute coronary syndromes. Complications involving the cardiovascular system include myocardial infarction, arrhythmias, shock, and heart failure. In this evidence-based review, we discuss risk factors of cardiovascular involvement in COVID-19 infection, pathophysiology of COVID-19-related cardiovascular infection, and injury, COVID-19 effects on the cardiovascular system and corresponding treatments, and hematologic effects of COVID-19 and COVID-19 in heart transplant patients. Clinicians managing COVID-19 patients should appreciate the potential cardiovascular effects related to the disease process.
Keywords: COVID; cardiovascular; coronavirus; healthcare; heart; hematology.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest Richard Urman reports unrelated research funding from AcelRx and fees from Medtronic, Merck, Pfizer, Heron, and Takeda. Alan Kaye reports fees from Merck. Other authors report no conflicts of interest.
References
-
- Matsushita K., Marchandot B., Jesel L., et al. Impact of COVID-19 on the cardiovascular system: a review. J Clin Med. 2020 May 9;9(5) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291320/ Available from: - PMC - PubMed
-
- Guzik T.J., Mohiddin S.A., Dimarco A., et al. 2020 Apr 30. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7197627/ Cardiovasc Res [Internet] - PMC - PubMed
-
- COVID-19 map [internet]. Johns hopkins coronavirus resource center. https://coronavirus.jhu.edu/map.html Available from:
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous